Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C1 | P04150 | 7/20 | 0.80 |
| ▸ | PGR | P06401 | 4/20 | 0.77 |
| ▸ | AR | P10275 | 3/20 | 0.77 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.77 |
| ▸ | HIF1A | Q16665 | 3/20 | 0.76 |
| ▸ | HRH1 | P35367 | 1/20 | 0.76 |
| ▸ | LMNA | P02545 | 3/20 | 0.72 |
| ▸ | FNTA | P49354 | 1/20 | 0.64 |
| ▸ | FNTB | P49356 | 1/20 | 0.64 |
| ▸ | SERPINA6 | P08185 | 2/20 | 0.60 |
| ▸ | SHBG | P04278 | 2/20 | 0.57 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.54 |
| ▸ | USP2 | O75604 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.53 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 1/20 | 0.53 |
| ▸ | MAPK3 | P27361 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13069232 | 1.00 | NR3C1 (0.80) | NR3C1PGRARHSD17B10HIF1A | |
| SCHEMBL21231580 | 1.00 | NR3C1 (0.80) | NR3C1PGRARHSD17B10HIF1A | |
| SCHEMBL3394719 | 1.00 | NR3C1 (0.80) | NR3C1PGRARHSD17B10HIF1A | |
| SCHEMBL7616035 | 0.92 | NR3C1 (0.80) | NR3C1PGRARHSD17B10HIF1A | |
| SCHEMBL3406859 | 0.92 | NR3C1 (0.80) | NR3C1PGRARHSD17B10HIF1A | |
| SCHEMBL11814061 | 0.90 | NR3C1 (0.77) | NR3C1PGRARHSD17B10HIF1A | |
| SCHEMBL11814068 | 0.90 | NR3C1 (0.77) | NR3C1PGRARHSD17B10HIF1A | |
| SCHEMBL8735123 | 0.90 | NR3C1 (0.87) | NR3C1PGRARHSD17B10HIF1A | |
| SCHEMBL8735124 | 0.90 | NR3C1 (0.87) | NR3C1PGRARHSD17B10HIF1A | |
| Fludrocortisone SCHEMBL21297043 | 0.89 | NR3C1 (0.96) | NR3C1PGRARHSD17B10HIF1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-4041055-A | SULFENYLATION, MICHAEL ADDITION, REACTION WITH THIOPHILE, HYDROLYSIS | THE UPJOHN COMPANY (US) | 1977-08-09 | — | — | US | claimed |
| EP-3426285-B1 | FORMULATIONS AND DOSES OF PEGYLATED URICASE | CARTESIAN THERAPEUTICS INC (US) | 2024-05-29 | — | — | EP | disclosed |
| US-20240100068-A1 | METHODS COMPRISING ADMINISTRATION OF A GLUCOCORTICOID RECEPTOR AGONIST AND AN INHIBITOR OF CALCINEURIN | CHENGDU ANTICANCER BIOSCIENCE LTD (CN) | 2024-03-28 | — | — | US | disclosed |
| US-20230107561-A1 | METHODS AND COMPOSITIONS RELATED TO COMBINED TREATMENT WITH ANTI-INFLAMMATORIES AND SYNTHETIC NANOCARRIERS COMPRISING AN IMMUNOSUPPRESSANT | SELECTA BIOSCIENCES, INC. (US) | 2023-04-06 | — | — | US | disclosed |
| EP-3980784-A1 | FORMULATIONS AND DOSES OF PEGYLATED URICASE | Selecta Biosciences, Inc. (US) | 2022-04-13 | — | — | EP | disclosed |
| US-11279729-B2 | Heterodimer compositions and methods for the treatment of ocular disorders | RIPPLE THERAPEUTICS CORPORATION (CA) | 2022-03-22 | — | — | US | disclosed |
| US-20210347809-A1 | HETERODIMER COMPOSITIONS AND METHODS FOR THE TREATMENT OF OCULAR DISORDERS | RIPPLE THERAPEUTICS CORPORATION (CA) | 2021-11-11 | — | — | US | disclosed |
| US-20210187081-A1 | FORMULATIONS AND DOSES OF PEGYLATED URICASE | SELECTA BIOSCIENCES, INC. (US) | 2021-06-24 | — | — | US | disclosed |
| US-20200399628-A1 | FORMULATIONS AND DOSES OF PEGYLATED URICASE | SELECTA BIOSCIENCES, INC. (US) | 2020-12-24 | — | — | US | disclosed |
| US-20200390718-A1 | METHODS AND COMPOSITIONS FOR ATTENUATED ANTI-VIRAL TRANSFER VECTOR IMMUNE RESPONSE | SELECTA BIOSCIENCES, INC. (US) | 2020-12-17 | — | — | US | disclosed |
| WO-2020247625-A1 | FORMULATIONS AND DOSES OF PEGYLATED URICASE | SELECTA BIOSCIENCES, INC. (GB) | 2020-12-10 | — | — | WO | disclosed |
| WO-2020243261-A1 | METHODS AND COMPOSITIONS FOR ATTENUATED ANTI-VIRAL TRANSFER VECTOR IMMUNE RESPONSE | SELECTA BIOSCIENCES, INC. (US) | 2020-12-03 | — | — | WO | disclosed |
| US-20180289776-A1 | METHODS AND COMPOSITIONS RELATED TO COMBINED TREATMENT WITH ANTIINFLAMMATORIES AND SYNTHETIC NANOCARRIERS COMPRISING AN IMMUNOSUPPRESSANT | SELECTA BIOSCIENCES, INC. | 2018-10-11 | — | — | US | disclosed |
| US-20170258927-A1 | FORMULATIONS AND DOSES OF PEGYLATED URICASE | SELECTA BIOSCIENCES, INC. | 2017-09-14 | — | — | US | disclosed |
| EP-2246359-A1 | Process for obtaining fluorometholone and intermediates therefor | Crystal Pharma, S.L.U. (ES) | 2010-11-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240100068-A1 | METHODS COMPRISING ADMINISTRATION OF A GLUCOCORTICOID RECEPTOR AGONIST AND AN INHIBITOR OF CALCINEURIN | PPP3R1, CHP1, NR3C1 | NR3C1 3/4885PGR 402/4885AR 387/4885 |
| US-11279729-B2 | Heterodimer compositions and methods for the treatment of ocular disorders | CRYAB, UACA, CRYAA | NR3C1 774/4885PGR 365/4885AR 2202/4885 |
| US-20210347809-A1 | HETERODIMER COMPOSITIONS AND METHODS FOR THE TREATMENT OF OCULAR DISORDERS | CRYAB, UACA, CRYAA | NR3C1 774/4885PGR 365/4885AR 2202/4885 |
| US-20200390718-A1 | METHODS AND COMPOSITIONS FOR ATTENUATED ANTI-VIRAL TRANSFER VECTOR IMMUNE RESPONSE | HAVCR2, CCL5, IRF3 | NR3C1 30/4885PGR 1498/4885AR 2643/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.